open access

Vol 15, No 2 (2018)
Review paper
Published online: 2018-06-27
Get Citation

„Legal highs” — what we know about novel psychoactive substances?

Bogumiła Lubecka, Marek Lubecki, Robert Pudlo
Psychiatria 2018;15(2):99-109.

open access

Vol 15, No 2 (2018)
Prace poglądowe - nadesłane
Published online: 2018-06-27

Abstract

In the last decade, despite the increasing health awarness of the public, a growing problem of addiction to new psychoactive
substances (NSP) is observed. These compounds, colloquially called „designer drugs”, until recently, available
in stationary shops, are currently purchased mainly through websides. Accepting these substances, as shown in recent
years, is associated not only with , addiction, but also with the hazard of poisoning, which can directly threaten health
and life. The phenomenon affects mainly young people, especially men. The main obstacle to the effective delegalisation
of new drugs is the rapid increase in their number, mainly due to the slight modification of the chemical composition
of existing substances, appearing in the list of narcotic drugs and psychotropic substances that is an annex to the Act
on counteracting drug addiction. In contrast, in clinical practice, the main problem is the lack of appropriate diagnostic
methods and standards of treatment in emergency procedures.
This article contains information about the NSP. The authors have assembled the material using the available academic
works, research papers ,case studies and their own medical practices.

Abstract

In the last decade, despite the increasing health awarness of the public, a growing problem of addiction to new psychoactive
substances (NSP) is observed. These compounds, colloquially called „designer drugs”, until recently, available
in stationary shops, are currently purchased mainly through websides. Accepting these substances, as shown in recent
years, is associated not only with , addiction, but also with the hazard of poisoning, which can directly threaten health
and life. The phenomenon affects mainly young people, especially men. The main obstacle to the effective delegalisation
of new drugs is the rapid increase in their number, mainly due to the slight modification of the chemical composition
of existing substances, appearing in the list of narcotic drugs and psychotropic substances that is an annex to the Act
on counteracting drug addiction. In contrast, in clinical practice, the main problem is the lack of appropriate diagnostic
methods and standards of treatment in emergency procedures.
This article contains information about the NSP. The authors have assembled the material using the available academic
works, research papers ,case studies and their own medical practices.

Get Citation

Keywords

„legal highs”, novel psychoactive substances (NSP), substance abuse

About this article
Title

„Legal highs” — what we know about novel psychoactive substances?

Journal

Psychiatria (Psychiatry)

Issue

Vol 15, No 2 (2018)

Article type

Review paper

Pages

99-109

Published online

2018-06-27

Bibliographic record

Psychiatria 2018;15(2):99-109.

Keywords

„legal highs”
novel psychoactive substances (NSP)
substance abuse

Authors

Bogumiła Lubecka
Marek Lubecki
Robert Pudlo

References (46)
  1. Oficjalna strona internetowa Europejskiego Centrum Monitorowania Narkotyków i Narkomanii (EMCDDA). http://www.emcdda.europa.eu (22.01.2017).
  2. Korczak J. Współczesne dopalacze – zjawisko i zagrożenia. In: Jędrzejko M. ed. Narkomania – spojrzenie wielowymiarowe. AH, Pułtusk-Warszawa 2009: 267–326.
  3. Wiszejko-Wierzbicka D, Kidawa M, Jabłońska M. Motywy zażywania i typologia użytkowników nowych substancji psychoaktywnych na podstawie badania sondażowego i analizy forów internetowych w ramach projektu I-TREND. Alcoholism and Drug Addiction. 2016; 29(2): 61–74.
  4. http://www emcdda europa eu/activities/action-on-newdrugs . (22.01.2017).
  5. Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39(2): 221–226.
  6. Zawilska J. Nowe związki psychoaktywne („dopalacze”). Część 1 Informacje ogólne. Med Prakt Psychiatria. 2016; 1: 45–50.
  7. Kołodziejczyk M. Impreza dla kolekcjonerów. Polityka. 2008; 2682: 26–28.
  8. Oficjalna strona Głównego Inspektoratu Sanitarnego. http://gis.gov.pl/zdrowie/dopalacze/dane-statystyczne (22.01.2017).
  9. Raport dopalacze 2016 Opracowanie przygotowane przez Wojewódzka Stacje Sanitarno-Epidemiologiczna w Katowicach Dział Nadzoru Sanitarnego oraz Oddział Epidemiologiczny. http://krpa.info/wp-content/uploads/2016/06/opracowanie-NS-EP-dot-dopalaczy-pdf (22.01.2017).
  10. Dziennik Ustaw z 2010 r. Nr 213, poz. 1396.
  11. Ustawa z dnia 24 kwietnia 2015 r. o zmianie ustawy o przeciwdziałaniu narkomanii oraz niektórych innych ustaw. Dz.U. 2015, poz. 875, s. 14-34.
  12. Ustawa z dnia 24 kwietnia 2015 r. o zmianie ustawy o przeciwdziałaniu narkomanii oraz niektórych innych ustaw. Dz.U. 2015, poz. 875, s. 12.
  13. Hughes B, Winstock AR. Controlling new drugs under marketing regulations. Addiction. 2012; 107(11): 1894–1899.
  14. Mazurkiewicz MR, Glogowski M, Mrowińska D, et al. Prevalence, reasons, and forms of use of legal highs by internet-based survey participants. Psychiatr Pol. 2013; 47(6): 1143–1155.
  15. Wiszejko-Wierzbicka D, Kidawa M, Jabłońska M. Motywy zażywania i typologia użytkowników nowych substancji psychoaktywnych na podstawie badania sondażowego i analizy forów internetowych w ramach projektu I-TREND. Alcoholism and Drug Addiction. 2016; 29(2): 61–74.
  16. hyperreal.info/talk. (22.01.2017).
  17. Wiszejko-Wierzbicka D, Kidawa M, Jabłońska M. Motywy zażywania i typologia użytkowników nowych substancji psychoaktywnych na podstawie badania sondażowego i analizy forów internetowych w ramach projektu I-TREND. Alcoholism and Drug Addiction. 2016; 29(2): 61–74.
  18. Antia U, Tingle MD, Russell BR. “Party pill” drugs – BZP and TFMPP. NZMJ. 2009; 122(1307): 55–68.
  19. Szajewski J. Dopalacze. Med Prakt. 2010; 10: 110–112.
  20. Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci. 2011; 5: 60.
  21. Auwärter V, Dresen S, Weinmann W, et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009; 44(5): 832–837.
  22. Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol. 2006; 1(1): 50–64.
  23. Cohen J, Morrison S, Greenberg J, et al. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics. 2012; 129(2): 1064–1067.
  24. Sikk K, Taba P. Methcathinone “Kitchen Chemistry” and Permanent Neurological Damage. International Review of Neurobiology. 2015: 257–271.
  25. Habrat B, Baran-Furga H, Sienkiewicz-Jarosz H, et al. Encephalopathy caused by intravenous potassium permanganate used for illegal production of methcathinone (ephedrone) from medicines containing pseudoephedrine. Przegl Lek. 2013; 70(8): 613–616.
  26. Kaizer-Będkowska M, Kucia K. Zaburzenia psychotyczne związane z używaniem „dopalaczy”. Psychiatria. 2017; 14(3): 162–167.
  27. Spiller H, Ryan M, Weston R, et al. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology. 2011; 49(6): 499–505.
  28. Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013; 108(3): 534–544.
  29. Seely KA, Prather PL, James LP, et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011; 11(1): 36–51.
  30. Forrester MB. Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse. 2012; 38(6): 609–615.
  31. Gunderson EW, Haughey HM, Ait-Daoud N, et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012; 21(4): 320–326.
  32. Adamowicz P. Analiza toksykologiczna nowych substancji psychoaktywnych (NSP) i ocena ich toksycznego działania na organizm ludzki. Autoreferat. Kraków. 2016: 10–12.
  33. Strano-Rossi S, Odoardi S, Fisichella M, et al. Screening for new psychoactive substances in hair by ultrahigh performance liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr A. 2014 [Epub ahead of print]; 1372C: 145–156.
  34. Tang MHY, Ching CK, Lee CYW, et al. Simultaneous detection of 93 conventional and emerging drugs of abuse and their metabolites in urine by UHPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 969: 272–284.
  35. Wohlfarth A, Weinmann W, Dresen S. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal Bioanal Chem. 2010; 396(7): 2403–2414.
  36. Adamowicz P, Tokarczyk B, Stanaszek R, et al. Fatal mephedrone intoxication--a case report. J Anal Toxicol. 2013; 37(1): 37–42.
  37. Helander A, Bäckberg M, Hultén P, et al. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int. 2014; 243: 23–29.
  38. Warrick BJ, Hill M, Hekman K, et al. A 9-state analysis of designer stimulant, "bath salt," hospital visits reported to poison control centers. Ann Emerg Med. 2013; 62(3): 244–251.
  39. Vevelstad M, Øiestad EL, Middelkoop G, et al. The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications. Forensic Sci Int. 2012; 219(1-3): 151–157.
  40. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012; 60(1): 103–105.
  41. Corkery JM, Elliott S, Schifano F, et al. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update. Hum Psychopharmacol. 2013; 28(4): 345–355.
  42. Balmelli C, Kupferschmidt H, Rentsch K, et al. [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. Dtsch Med Wochenschr. 2001; 126(28-29): 809–811.
  43. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol. 2000; 10(4): 289–295.
  44. Hysek CM, Vollenweider FX, Liechti ME. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J. 2010; 27(8): 586–589.
  45. Hysek CM, Fink AE, Simmler LD, et al. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol. 2013; 33(5): 658–666.
  46. Hysek CM, Schmid Y, Rickli A, et al. Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol. 2012; 166(8): 2277–2288.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl